Importantly, clinical validation of human breast cancer samples reveals a significant correlation between high expression of TβRI and FBXO3 with low expression of p63 and that breast cancer patients with high TβRI/FBXO3 or low p63 exhibit poor RFS. This evidence concerns the gene FBXO3 and breast carcinoma.